calculation of 90% CI for continuous variable in clinical endpoint studies [General Sta­tis­tics]

posted by DavidManteigas – Portugal, 2017-11-21 11:01 (2024 d 23:42 ago) – Posting: # 17996
Views: 4,440

Hi GM,

As El Maestro explained, when your test hypothesis is a ratio (multiplicative model) then you must work with ln transformed data. The guidance is clear on that as it also defines the acceptance range as 0.8 to 1.25 (multiplicative model). If in some guideline they state the hypothesis as treatment differences (H0: u1-u2=0) and a symmetric equivalence range (0.8 to 1.2) then they would be suggesting an analysis on untransformed data. This is true regardless of the type of your endpoint as long as it is a continuous endpoint. As simple as that ;-)


Complete thread:

UA Flag
 Admin contact
22,620 posts in 4,741 threads, 1,612 registered users;
30 visitors (0 registered, 30 guests [including 19 identified bots]).
Forum time: 11:44 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz